DOV Pharmaceutical

DOV Pharmaceutical, was a biotechnology company, focuses on therapies primarily for central nervous system conditions. The firm's lead drug candidate, Indiplon, is said to treat insomnia. Indiplon targets the same subset of neurotransmitter receptors affected by Valium and Xanax, but with more specificity to avoid the side effects associated with those drugs. DOV Pharmaceutical, Neurocrine Biosciences, and Pfizer are working on the candidate. Other candidates in DOV's pipeline target depression and angina, pain, anxiety, high blood pressure, and other disorders.

References

• Hess, Diane, Drugmaker's IPO Is a Big Headache, TheStreet.com, 1 May 2002. Retrieved 5 November 2007.
• Simpson, Stephen D. A Pain DOV Pharmaceutical Couldn't Cure, Motley Fool, 26 April 2006. Retrieved 5 November 2007.
• Krauskopf, Lewis, Investors Suing Hackensack, N.J.-Based DOV Pharmaceutical over Stock Losses, The Record (Hackensack, New Jersey), 2 May 2002. Retrieved 5 November 2007.
• Lynn, Kathleen, Dov Pharmaceutical exploring alternatives, The Record (Hackensack, New Jersey), 11 October 2006. Retrieved 5 November 2007.
• Maeillo, Michael, The Coldest IPO..., Forbes.com, 2 September 2002. Retrieved 5 November 2007.
• DOV IPO sinks on first day, CNN.com, 25 April, 2002. Retrieved 5 November 2007.
• DOV Pharmaceutical Inc. (DOVP), Wall Street Journal profile. Retrieved 5 November 2007.

External links

Company web site

• • Business data for DOV Pharmaceutical Inc.:
  • Hoover's
  • Reuters
  • SEC filings